RY

170.6

-0.64%↓

TD

94.22

-0.55%↓

BMO

129.87

-0.45%↓

BNS

73.71

-0.32%↓

CM

90.65

-0.92%↓

RY

170.6

-0.64%↓

TD

94.22

-0.55%↓

BMO

129.87

-0.45%↓

BNS

73.71

-0.32%↓

CM

90.65

-0.92%↓

RY

170.6

-0.64%↓

TD

94.22

-0.55%↓

BMO

129.87

-0.45%↓

BNS

73.71

-0.32%↓

CM

90.65

-0.92%↓

RY

170.6

-0.64%↓

TD

94.22

-0.55%↓

BMO

129.87

-0.45%↓

BNS

73.71

-0.32%↓

CM

90.65

-0.92%↓

RY

170.6

-0.64%↓

TD

94.22

-0.55%↓

BMO

129.87

-0.45%↓

BNS

73.71

-0.32%↓

CM

90.65

-0.92%↓

Search

Houlihan Lokey Inc

Gesloten

SectorFinanciën

173.91 -1.14

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

173.22

Max

175.81

Belangrijke statistieken

By Trading Economics

Inkomsten

14M

112M

Verkoop

54M

659M

K/W

Sectorgemiddelde

28.672

25.743

Dividendrendement

1.31

Winstmarge

16.951

Werknemers

2,702

EBITDA

35M

179M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.06% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.31%

3.67%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.7B

12B

Vorige openingsprijs

175.05

Vorige sluitingsprijs

173.91

Nieuwssentiment

By Acuity

100%

0%

492 / 526 Rangschikking in Finance

Houlihan Lokey Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 dec 2025, 22:20 UTC

Belangrijke Marktbewegers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dec 2025, 17:31 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dec 2025, 16:30 UTC

Belangrijke Marktbewegers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dec 2025, 15:19 UTC

Belangrijke Marktbewegers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dec 2025, 15:17 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dec 2025, 14:37 UTC

Belangrijke Marktbewegers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dec 2025, 20:40 UTC

Marktinformatie

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dec 2025, 20:22 UTC

Marktinformatie

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dec 2025, 19:50 UTC

Marktinformatie

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dec 2025, 19:31 UTC

Marktinformatie

Precious Metals Cap Off Record Runs -- Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dec 2025, 17:17 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dec 2025, 17:16 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

31 dec 2025, 17:00 UTC

Acquisities, Fusies, Overnames

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dec 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dec 2025, 15:54 UTC

Marktinformatie

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dec 2025, 15:02 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dec 2025, 14:40 UTC

Acquisities, Fusies, Overnames

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dec 2025, 14:20 UTC

Marktinformatie

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dec 2025, 13:46 UTC

Marktinformatie

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dec 2025, 13:01 UTC

Winsten
Acquisities, Fusies, Overnames

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dec 2025, 11:10 UTC

Marktinformatie

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dec 2025, 10:46 UTC

Marktinformatie

Euro on Track For Strong Annual Performance -- Market Talk

31 dec 2025, 10:25 UTC

Marktinformatie

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dec 2025, 10:23 UTC

Marktinformatie

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dec 2025, 09:33 UTC

Marktinformatie

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer Vergelijking

Prijswijziging

Houlihan Lokey Inc Prognose

Koersdoel

By TipRanks

23.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 216.4 USD  23.06%

Hoogste 235 USD

Laagste 193 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Houlihan Lokey Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Sentiment

By Acuity

492 / 526 Rangschikking in Financiën

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Houlihan Lokey Inc

Houlihan Lokey, Inc., an investment banking company, provides merger and acquisition (M&A), capital market, financial restructuring, and financial and valuation advisory services in the United States and internationally. It operates in three segments: Corporate Finance (CF), Financial Restructuring (FR), and Financial and Valuation Advisory (FVA). The CF segment offers general financial advisory services; and advises public and private institutions on buy-side and sell-side transactions, leveraged loans, private mezzanine debt, high-yield debt, initial public offerings, follow-ons, convertibles, equity private placements, private equity, and liability management transactions, as well as financial sponsors on various transactions. The FR segment advises debtors, creditors, and other parties-in-interest related to recapitalization/deleveraging transactions. This segment also provides a range of advisory services, including structuring, negotiation, and confirmation of plans of reorganization; structuring and analysis of exchange offers; corporate viability assessment; dispute resolution and expert testimony; and procuring debtor-in-possession financing. The FVA segment offers valuations of various assets, such as companies, illiquid debt and equity securities, and intellectual property; and dispute resolution services. This segment also provides fairness opinions in connection with M&A and other transactions, solvency opinions in connection with corporate spin-offs and dividend recapitalizations, and other types of financial opinions. The company serves corporations, financial sponsors, and government agencies. Houlihan Lokey, Inc. was incorporated in 1972 and is headquartered in Los Angeles, California.
help-icon Live chat